Researchers from KU Leuven, the University of California Davis Medical Center, the University of Cologne, and over 20 collaborating institutions report that the antifungal olorofim demonstrated efficacy and tolerability in patients with invasive fungal disease who had exhausted most other treatment options.
Olorofim Phase IIb trial shows efficacy in invasive fungal disease for patients with limited treatment options
-
HighlightsFree Dark Web Monitoring Stamps the $17 Million Credentials Markets
-
HighlightsSmart buildings: What happens to our free will when tech makes choices for us?
-
AppsScreenshots have generated new forms of storytelling, from Twitter fan fiction to desktop film
-
HighlightsDarknet markets generate millions in revenue selling stolen personal data, supply chain study finds
-
SecurityPrivacy violations undermine the trustworthiness of the Tim Hortons brand
-
Featured HeadlinesWhy Tesla’s Autopilot crashes spurred the feds to investigate driver-assist technologies – and what that means for the future of self-driving cars
